Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of Concurrent Ipilimumab Therapy and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Malignant Melanoma

NCT01565837 is registered in ClinicalTrials.gov with Wolfram Samlowski as lead sponsor.

NCT NCT01565837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01565837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of Concurrent Ipilimumab Therapy and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Malignant Melanoma
Lead sponsor
Wolfram Samlowski
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2012
Completion date
November 30, 2017
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma